Skip to main content

Kansas PKD Research and Translation Core Center

james calvet
The mission of our PKD Center is to promote research leading to a better understanding of PKD through the discovery of therapy targets and development of clinical trials to improve patient outcomes. The National Institute of Diabetes and Digestive and Kidney Diseases at the NIH awarded the Kansas PKD Center a five-year Center Grant (P30) that provides $5.4 million in funding to support our innovative biomedical research cores and a robust pilot and feasibility program.


Chris Ward

Gene Targeting Core - provides expert CRISPR/TALEN gene-editing for the generation of unique PKD animal models and cell lines for the identification of new targets for drug development. The goal of the Core is to assist PKD investigators in the generation of unique animal models and cell lines using TALENS or CRISPRs to help them solve complex PC1/PC2 signaling questions.

PI: Chris Ward, Ph.D.

Xiaogang Li and Ken Peterson

Epigenetics Core - provides services and reagents to facilitate the efforts of PKD investigators in this new and exciting frontier in PKD science. The goal of the Epigenetics Core is to help PKD researchers understand and investigate the mechanisms by which transcriptional and epigenetic regulation are disrupted in PKD, and to use this information to develop specific and effective therapeutic strategies.

PIs:  Ken Peterson, Ph.D. and Robin Maser, Ph.D.

Darren Wallace

Biomarkers Core - supports investigators in biomedical research involved in the discovery, validation and development of biomarkers for early PKD. The long term goal of the Core is to establish a panel of blood and/or urine biomarkers that will provide a minimally invasive approach to predict early PKD progression and to monitor the response to clinical treatment.

  > Now enrolling patients in the PKD Biomarkers Study

PI: Darren Wallace, Ph.D.

Alan Yu

Clinical Research Core - facilitates clinical and translational research in PKD, with a focus on investigator-initiated studies that bridge the gap between preclinical studies and early phase clinical trials. This will be achieved through the provision of consultative advice on drug development, a patient registry network for clinical trials recruitment, resources and services for conducting clinical trials, and a searchable integrated clinical data repository for observational research.

PI: Alan Yu, M.B., B.Chir.

Last modified: Aug 13, 2018